Hematological Oncology最新文献

{"title":"DELIVERY OF EMERGENCY CARE FOR PATIENTS WITH LYMPHOMA IN A DEDICATED FACILITY BY ADVANCED NURSE PRACTITIONERS","authors":"M. Fowler","doi":"10.1002/hon.70093_ON01","DOIUrl":"https://doi.org/10.1002/hon.70093_ON01","url":null,"abstract":"<p><b>Introduction:</b> Patients with lymphoma often experience acute complications, including infections, disease progression, and treatment-related side effects, necessitating urgent medical attention. Traditional emergency departments may not provide optimal care due to long wait times and a lack of specialist haemato-oncology expertise. To address these challenges, our institution established a dedicated emergency care facility for all patients with cancer, staffed by advanced nurse practitioners (ANPs). This service aims to improve access to timely, expert-driven emergency care while reducing unnecessary hospital admissions.</p><p><b>Methods:</b> The dedicated emergency care facility is staffed by experienced ANPs with specialist haemato-oncology training. All ANPs have a dedicated MSc in Advanced Clinical Practice and the unit also supports trainee ANPs completing their MSc programme. The service operates 7 days per week, providing rapid assessment, symptom management, and coordination with haematology teams. ANPs perform comprehensive patient assessments, prescribe medications (including blood product authorisation), initiate diagnostics, manage acute complications, and determine appropriate interventions, including outpatient treatment, rapid specialist referrals, or hospital admission if necessary. A multidisciplinary approach ensures continuity of care and optimal patient outcomes.</p><p><b>Results:</b> Since its implementation, the service has enhanced the efficiency of emergency care for lymphoma patients. Wait times for assessment have significantly decreased, and hospital admission rates have been reduced by providing timely interventions in an ambulatory setting. The ANP-led model has improved patient satisfaction, with high ratings for accessibility, communication, and symptom management. Additionally, collaboration with haemato-oncology specialists has streamlined patient pathways, ensuring prompt escalation of care when needed.</p><p><b>Conclusions:</b> A dedicated ANP-led emergency care facility provides a safe, efficient, and patient-centered approach to managing lymphoma-related emergencies. This model enhances the quality of care while alleviating pressure on emergency departments. Its success highlights the critical role of ANPs in specialist acute haemato-oncology services, with potential for replication in other cancer centres.</p><p><b>Research</b> <b>funding declaration:</b> Nil</p><p><b>Keywords:</b> outpatient developments and ambulatory care</p><p>No potential sources of conflict of interest.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_ON01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM): AN ALL-ORAL TREATMENT","authors":"B. Dhakal,&nbsp;M. Hultcrantz,&nbsp;N. Nathwani,&nbsp;C. P. Venner,&nbsp;J. Lu,&nbsp;M. J. Slade,&nbsp;J. L. Kaufman,&nbsp;H. Chuah,&nbsp;C. Min,&nbsp;K. Kim,&nbsp;H. Cheng,&nbsp;A. Idoine,&nbsp;W. Zhang,&nbsp;X. Wang,&nbsp;A. Agarwal,&nbsp;H. Quach","doi":"10.1002/hon.70093_123","DOIUrl":"https://doi.org/10.1002/hon.70093_123","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Introduction:&lt;/b&gt; Despite the clinical efficacy of BCL2 inhibition in t(11;14)-positive MM, no BCL2-targeted treatments (tx) are approved. Sonrotoclax (sonro; BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no drug accumulation. BGB-11417-105 (NCT04973605) is an ongoing phase 1b/2 study of sonro as mono- or combination tx in patients (pts) with t(11;14)-positive R/R MM. Updated results in pts treated with sonro + dexamethasone (dex) are presented.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; Eligible pts had R/R MM with centrally confirmed t(11;14) and received oral sonro (320 or 640 mg QD) + dex (40 mg QW). Tx-emergent adverse events (TEAEs) were graded by CTCAE v5.0 and efficacy was assessed by the investigator per IMWG criteria.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; As of January 20, 2025, 14 and 36 evaluable pts were enrolled in the sonro 320-mg and 640-mg cohorts, respectively; median (range) follow-up was 6.2 mo (2.6–34.5) and 12.1 mo (0.1–28.9), respectively. The median (range) prior lines of tx were 3 (1–7) in the 320-mg cohort and 3 (1–12) in the 640-mg cohort; 78.6% and 66.7% of pts were refractory to 3 tx classes, respectively. At data cutoff, 7 pts (50.0%) in the 320-mg cohort and 14 (38.9%) in the 640-mg cohort remained on tx; progression was the most common reason for discontinuation (35.7% and 41.7%, respectively). The ORR (95% CI) was 64.3% (35.1–87.2) in the 320-mg cohort and 80.6% (64.0–91.8) in the 640-mg cohort, with VGPR or better rates (95% CI) of 35.7% (12.8–64.9) and 55.6% (38.1–72.1), respectively (Figure). The median time to response was 0.7 mo in both cohorts. Median (95% CI) duration of response was 5.9 mo (1.8-not estimable [NE]) in the 320-mg cohort and 12.2 mo (8.3–18.9) in the 640-mg cohort. Median (95% CI) PFS was 6.6 mo (2.9-NE) in the 320-mg cohort and 13.3 mo (9.0–19.6) in the 640-mg cohort.&lt;/p&gt;&lt;p&gt;The most common TEAEs were fatigue (35.7%) in the 320-mg cohort, and insomnia (38.9%) and diarrhea (38.9%, all grade 1/2) in the 640-mg cohort. Grade ≥ 3 TEAEs occurred in 5 pts (35.7%) in the 320-mg cohort and 17 pts (47.2%) in the 640-mg cohort; serious TEAEs occurred in 3 (21.4%) and 10 (27.8%), respectively. Grade ≥ 3 hematologic TEAEs occurred in 1 (7.1%) and 9 (25.0%) and grade ≥ 3 infections in 3 (21.4%) and 4 (11.1%) pts, respectively. Two pts (14.3%) in the 320-mg cohort and 2 (5.6%) in the 640-mg cohort died during the tx-emergent part for reasons unrelated to tx (320 mg, pneumonia RSV and COVID-19; 640 mg, hypoventilation [related to pulmonary involvement with PD] and metastatic pancreatic cancer). Four more deaths occurred &gt; 30 d after the last 640-mg dose.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; This ongoing study showed that the all-oral combination of sonro + dex is tolerable, with low rates of infection and hematologic toxicity, and promising efficacy, with an ORR of 81% in the 640-mg cohort, in this t(11;14)-positive R/R MM population.","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_123","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NODAL MARGINAL ZONE LYMPHOMA: MUTATIONAL ANALYSIS, GENE EXPRESSION PROFILE, AND DIFFERENTIAL DIAGNOSIS FROM OTHER SMALL B-CELL LYMPHOMAS","authors":"V. Borgmann,&nbsp;H. S. Gierer,&nbsp;S. Paigin,&nbsp;I. Bonzheim,&nbsp;F. Fend,&nbsp;D. Nann,&nbsp;L. Quintanilla-Martinez","doi":"10.1002/hon.70094_253","DOIUrl":"https://doi.org/10.1002/hon.70094_253","url":null,"abstract":"&lt;p&gt;D. Nann equally contributing author.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Objective&lt;/b&gt;: Nodal Marginal zone lymphoma (NMZL) represents 1.5%–1.8% of NHL. NMZL diagnosis is based on a combination of morphological and immunophenotypic features. Due to the absence of disease-defining phenotypic/genetic markers in NMZL, the differential diagnosis with other NHL, especially &lt;i&gt;BCL2&lt;/i&gt; rearrangement-negative follicular lymphoma (&lt;i&gt;BCL2&lt;/i&gt;-R-neg FL) can be challenging. We performed mutational analysis to investigate whether these might help in separating NMZL from other small B-cell lymphomas. Additionally, NMZL GEP was compared to the genetic profile of &lt;i&gt;BCL2&lt;/i&gt;-R-neg FL obtained in a previous study.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Material and Methods:&lt;/b&gt; 52 cases with the diagnosis of NMZL were selected. All cases were comprehensively immunophenotyped. &lt;i&gt;BCL2&lt;/i&gt; and &lt;i&gt;BCL6&lt;/i&gt; FISH analyses were performed in selected cases. Targeted NGS analysis was done on the Ion GeneStudio S5 Prime (ThermoFisher). NGS libraries were amplified using a custom Oncomine lymphoma panel (ThermoFisher) covering 82 genes frequently mutated in B-cell NHL. GEP was performed using the nCounter PanCancer Immune profiling panel from NanoString.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; The 52 cases included 30 women and 22 men with a mean age of 67 years (range 36–89). After morphological and mutational analyses 38 cases were confirmed as NMZL (73%) and 14 cases (27%) were reclassified as a different NHL. The most difficult differential diagnosis was with &lt;i&gt;BCL2&lt;/i&gt;-R-neg FL (8/52; 15%), including four CD23+ cases harboring &lt;i&gt;STAT6&lt;/i&gt; mutations co-occurring with &lt;i&gt;CREBBP&lt;/i&gt; and/or &lt;i&gt;TNFRSF14&lt;/i&gt; mutations. The other 4 cases were reclassified as &lt;i&gt;BCL2&lt;/i&gt;-R-neg FL based on the expression of at least one GC marker and the mutational profile; 3 showed &lt;i&gt;BCL6&lt;/i&gt;-R. Six cases (6/52; 11.5%) were reclassified as CLL based on morphology and a mutational profile compatible with CLL (&lt;i&gt;ATM, BIRC3, NOTCH1, TP53&lt;/i&gt;). All 6 cases had an atypical phenotype, either CD5 and/or CD23 negativity. In 33/38 NMZL cases (87%), 118 pathogenic mutations were identified (3.57 mutation/per case). The most frequently mutated gene was &lt;i&gt;KLF2&lt;/i&gt; (13/38; 34%), followed by &lt;i&gt;KMT2D&lt;/i&gt; (8/38; 21%), &lt;i&gt;TBL1XR1&lt;/i&gt;, (6/38; 16%), &lt;i&gt;TET2, CREBBP&lt;/i&gt;, &lt;i&gt;HIST1H1E, BTG2, FAS&lt;/i&gt; (4/38; 11%), &lt;i&gt;MYD88, SPEN&lt;/i&gt;, &lt;i&gt;ARID1A, NOTCH2, TNFRSF14&lt;/i&gt; (3/38; 8%), &lt;i&gt;BCL10, ARID1B&lt;/i&gt;, &lt;i&gt;ID3, HLA-B, CD70, SOCS1,&lt;/i&gt; (2/38; 5%), and others (see figure). Unsupervised clustering of GEP correlated with the final pathological classification and separated NMZL from the &lt;i&gt;BCL2&lt;/i&gt;-R-neg FL &lt;i&gt;STAT6&lt;/i&gt; mut cases. However, some &lt;i&gt;BCL2&lt;/i&gt;-R-neg FL &lt;i&gt;STAT6&lt;/i&gt; wt cases clustered with NMZL. NMZL showed upregulation of genes involved in Toll receptor cascades (&lt;i&gt;TLR1, TLR7, MAP3K1&lt;/i&gt;), cytokine interactions (&lt;i&gt;TNFSF18, CXCR3, IL6, TNFRSF15, CCR6&lt;/i&gt;), and innate immune system.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; Mutational analysis is useful for the differential diagnosis of NMZL","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70094_253","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MULTI-TARGETED THERAPY WITH VIPOR-P IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE","authors":"C. Melani,&nbsp;R. Lakhotia,&nbsp;S. Pittaluga,&nbsp;J. D. Phelan,&nbsp;J. Muppidi,&nbsp;M. Gordon,&nbsp;Y. Yang,&nbsp;W. Xu,&nbsp;T. Davies-Hill,&nbsp;D. W. Huang,&nbsp;C. J. Thomas,&nbsp;M. Ceribelli,&nbsp;F. A. Tosto,&nbsp;A. M. Juanitez,&nbsp;A. Pradhan,&nbsp;C. Morrison,&nbsp;A. Tadese,&nbsp;A. Jacob,&nbsp;H. Simmons,&nbsp;E. S. Jaffe,&nbsp;M. Roschewski,&nbsp;L. M. Staudt,&nbsp;W. H. Wilson","doi":"10.1002/hon.70094_316","DOIUrl":"https://doi.org/10.1002/hon.70094_316","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Introduction:&lt;/b&gt; Targeted ViPOR therapy leads to durable remissions in R/R non-GCB DLBCL (Melani et al. &lt;i&gt;Blood.&lt;/i&gt; 2024). We hypothesized that polatuzumab may improve outcomes and conducted a Phase I/II study of ViPOR-P. Here, we present updated efficacy and new MRD data from our ongoing ViPOR-P study.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; R/R DLBCL pts with adequate organ function were eligible. Polatuzumab 1.8 mg/kg IV D2, venetoclax 800 mg PO D2–14, ibrutinib 560 mg PO D1–14, prednisone 100 mg PO D1–7, obinutuzumab 1000 mg IV D1–2, and lenalidomide 15 mg PO D1–14 were given as previously described (Melani et al. &lt;i&gt;Blood&lt;/i&gt;. 2024). ViPOR-P q21d × 6C was given without maintenance or consolidation. All pts received TLS and G-CSF ppx. Baseline CT, PET, BM, and tumor bx was performed with CT scans after C2, 4, and 6 and PET after C6. Surveillance CT was performed q3m × 1y, q4m × 1y, q6m × 1y, and q12m × 2y. MRD was assessed in plasma ctDNA using clonoSEQ at baseline, during tx, and in f/u.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; 40 DLBCL pts (15 in Ph 1 &amp; 25 in Ph 2) enrolled. Median (range) age was 55y (23–83) with 73% male. 22 (55%) pts had non-GCB DLBCL, 11 (28%) HGBCL-DH-&lt;i&gt;BCL2&lt;/i&gt;, 4 (10%) THRLBCL, 2 (5%) HGBCL-DH-&lt;i&gt;BCL6&lt;/i&gt;, and 1 (3%) GCB DLBCL. Stage III/IV disease was seen in 83% with IPI &gt; 3 in 55%. Median (range) prior tx were 2 (1–6), with prior CAR-T in 40% and 53% of pts refractory per SCHOLAR-1.&lt;/p&gt;&lt;p&gt;G3–4 heme AEs (% cycles) included thrombocytopenia (26%), neutropenia (21%), and anemia (13%), with 2 febrile neutropenia events in 145 total cycles. All grade non-heme AEs (% pts) included hypokalemia (97%), diarrhea (76%), elevated LFTs (53%), and nausea (50%). G1–2 neuropathy occurred in 26% with no G3–4 neuropathy seen. 1 uncomplicated TLS event occurred and there was no tx-related mortality. Dose reductions occurred in 32% of pts, and 2 pts prematurely stopped tx due to toxicity.&lt;/p&gt;&lt;p&gt;In 36 evaluable pts off-tx, ORR was 78% (28/36) and CR rate was 56% (20/36). By IHC, CR rate was 67% (16/24) in non-GCB and 33% (4/12) in GCB, with all GCB CRs in HGBCL-DH-&lt;i&gt;BCL2&lt;/i&gt;. By RNA-seq, CR rate was 78% (7/9) in ABC, 45% (5/11) in GCB, and 100% (1/1) in unclassified DLBCL. In refractory and post-CAR-T pts, CR rate was 40% (8/20) and 38% (6/16), respectively. In 29 MRD evaluable pts, 66% (19/29) of all pts and 100% (18/18) of PET CR pts were MRD undetectable at EOT (Figure 1A). Undetectable MRD after C1 or at EOT was associated with improved PFS. With a median f/u of 28m, 71% of CRs are ongoing with a 2y PFS and OS of 41% and 53%, respectively. 2y PFS was 49% in non-GCB and 25% in GCB by IHC (Figure 1B), and 67% in ABC and 27% in GCB by RNA-seq. In refractory and post-CAR-T pts, 2y PFS was 22% and 26%, respectively.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; ViPOR-P × 6C leads to durable undetectable MRD CRs in R/R DLBCL, especially non-GCB and ABC subtypes, further validating the curative potential of ViPOR-based treatment. Compared to ViPOR, ViPOR-P is safe without sig","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70094_316","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PROGNOSTIC IMPACT OF EXTRANODAL INFILTRATION BASED ON ANATOMIC LOCATIONS AT PLASMABLASTIC LYMPHOMA DIAGNOSIS IN A MULTICENTRIC SPANISH SERIES (GELTAMO)","authors":"F. Martin-Moro,&nbsp;A. Jimenez-Ubieto,&nbsp;M. Gomez-Llobell,&nbsp;P. Gomez-Prieto,&nbsp;M. Alcoceba,&nbsp;S. Romero,&nbsp;P. Abrisqueta,&nbsp;P. Villafuerte,&nbsp;A. P. Gonzalez,&nbsp;R. Cordoba,&nbsp;M. Valero,&nbsp;M. B. Navarro,&nbsp;S. Huerga,&nbsp;D. Garcia,&nbsp;A. Garcia-Noblejas,&nbsp;E. Gonzalez-Barca,&nbsp;F. Diaz,&nbsp;J. Lopez-Jimenez,&nbsp;J. M. Sancho,&nbsp;J. T. Navarro,&nbsp;M. Bastos-Oreiro","doi":"10.1002/hon.70094_315","DOIUrl":"https://doi.org/10.1002/hon.70094_315","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Background:&lt;/b&gt; Plasmablastic lymphoma (PBL) is a rare and aggressive neoplasm with biological complexity and poor prognosis despite intensive therapy. Our aims were to evaluate the prognostic impact of extranodal involvement (ENi) at different locations at PBL diagnosis, and to stratify outcomes accordingly.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; Multicentric retrospective study on behalf of the Spanish Lymphoma Group (GELTAMO) including &lt;i&gt;de novo&lt;/i&gt; PBL. ENi at diagnosis was described and patients were grouped by anatomic locations. The impact on event-free survival (EFS) of each EN site was evaluated according to univariate hazard ratio (UV HR) by Cox regression model. Prognostic groups were established by Kaplan-Meier curves for both progression-free survival (PFS) and overall survival (OS). PFS was defined as the time from diagnosis to relapse/refractoriness (r/r), OS from diagnosis to death by any cause, and EFS from diagnosis to r/r or death by any cause.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; We included 69 PBL with a median age of 57 (IQR 42–72), 78% males, and 36% HIV positive. Median follow-up was 17 months (IQR 8–56). ENi was seen in 60 (87%): bone/muscle 23/60 (38%), gastrointestinal (GI)/liver 16/60 (27%), bone marrow (BM) 19/60 (32%), lung/pleura 11/60 (18%), skin/mucosa 10/60 (17%), central nervous system (CNS)/testes 9/60 (15%), and genitourinary (GU)/adrenal 6/60 (10%). In UV analyses, EFS HR (95%CI) according to ENi was as follows: any ENi 2.9 (0.9–9.6; &lt;i&gt;p&lt;/i&gt; = 0.07); BM 2.9 (1.6–5.4; &lt;i&gt;p&lt;/i&gt; &lt; 0.001), GU/adrenal 2.5 (1.1–5.9; &lt;i&gt;p&lt;/i&gt; = 0.04), lung/pleura 2 (1–4; &lt;i&gt;p&lt;/i&gt; = 0.06), CNS/testes 1.7 (0.8–3.8; &lt;i&gt;p&lt;/i&gt; = 0.2), bone/muscle 1.3 (0.7–2.3; &lt;i&gt;p&lt;/i&gt; = 0.4), GI/liver 0.8 (0.4–1.5; &lt;i&gt;p&lt;/i&gt; = 0.5), and skin/mucosa 0.6 (0.2–1.6; &lt;i&gt;p&lt;/i&gt; = 0.3). After including BM and GU/adrenal involvement in multivariate analysis, the BMi retained its impact on EFS (HR 2.7, 95% CI: 1.5–5.1; &lt;i&gt;p&lt;/i&gt; = 0.002) while GU/adrenal did not (HR 1.7, 95% CI: 0.7–4.2; &lt;i&gt;p&lt;/i&gt; = 0.3). The same happened when analyzed together BM (EFS HR 2.8, 95% CI: 1.5–5.2; &lt;i&gt;p&lt;/i&gt; = 0.001) and lung/pleura (EFS HR 1.7, 95% CI: 0.8–3.5; &lt;i&gt;p&lt;/i&gt; = 0.1). In UV analysis only including cases with ENi, BMi showed an EFS HR of 2.7 (95% CI: 1.5–5; &lt;i&gt;p&lt;/i&gt; = 0.001). Figure 1A presents the correlation between BM and other EN locations. Cases with isolated BMi as ENi (&lt;i&gt;N&lt;/i&gt; = 8) showed equivalent EFS than those with BM and any other ENi (&lt;i&gt;N&lt;/i&gt; = 11) (UV HR 1.1, 95% CI: 0.4–2.8; &lt;i&gt;p&lt;/i&gt; = 0.9). PBLs were clustered into three prognostic groups (Figure 1B): no ENi (2-year PFS 86% and OS 65%), ENi at any location except for BM (2-year PFS 53% and OS 53%), and BMi (2-year PFS 9% and OS 14%). Cases with BMi presented with a median age of 57 (IQR 54–73) and 16/19 (84%) were treated with curative intention, equivalent to cases without BMi: median age 55 (IQR 40–71; &lt;i&gt;p&lt;/i&gt; = 0.9) and 43/50 (86%; &lt;i&gt;p&lt;/i&gt; = 0.9) received intensive therapy.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; ENi at certain locations i","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70094_315","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD30 CAR-T IN RELAPSED AND REFRACTORY CD30+ LYMPHOMAS: LONG-TERM FOLLOW-UP OF A PHASE IB/II CLINICAL TRIAL","authors":"D. Reef,&nbsp;C. Cheng,&nbsp;C. Babinec,&nbsp;D. Burton,&nbsp;J. West,&nbsp;K. Morrison,&nbsp;F. Buchanan,&nbsp;A. Zanter,&nbsp;A. Spruill,&nbsp;K. Kasow,&nbsp;J. Serody,&nbsp;C. Dittus,&nbsp;G. Hucks,&nbsp;P. Armistead,&nbsp;B. Savoldo,&nbsp;G. Dotti,&nbsp;A. Beaven,&nbsp;N. Grover","doi":"10.1002/hon.70093_141","DOIUrl":"https://doi.org/10.1002/hon.70093_141","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Introduction:&lt;/b&gt; CD30 CAR-T is active and safe in relapsed/refractory (r/r) CD30&lt;sup&gt;+&lt;/sup&gt; lymphomas, including classic Hodgkin lymphoma (cHL) and mature T-cell lymphomas (MTCLs). Here, we share long-term follow-up from our phase Ib/II trial (NCT02690545).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; Following cell procurement and CD30 CAR-T manufacturing, patients (pts) received lymphodepletion (LD) followed by CAR-T infusion. Pts could receive bridging between procurement and LD. Two dose levels were assessed in a 3+3 design: 1x10&lt;sup&gt;8&lt;/sup&gt; CAR&lt;sup&gt;+&lt;/sup&gt; cells/m&lt;sup&gt;2&lt;/sup&gt; (DL1) and 2x10&lt;sup&gt;8&lt;/sup&gt; CAR&lt;sup&gt;+&lt;/sup&gt; cells/m&lt;sup&gt;2&lt;/sup&gt; (DL2). Once dose escalation was completed in adults, children were enrolled on the phase Ib portion. Inclusion criteria include r/r CD30&lt;sup&gt;+&lt;/sup&gt; lymphoma after ≥ 2 therapies and Karnofsky/Lansky performance status &gt; 60%. LD was initially bendamustine (benda) 90 mg/m&lt;sup&gt;2&lt;/sup&gt;/day on days −5 to −4, but was changed to fludarabine (flu) 30 mg/m&lt;sup&gt;2&lt;/sup&gt;/day and benda 70 mg/m&lt;sup&gt;2&lt;/sup&gt;/day on days -5 to -3 for efficacy.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; 34 pts received CD30 CAR-T 1/10/2017 to 3/11/2024, including 29 with cHL and 4 with MTCLs (ALK&lt;sup&gt;+&lt;/sup&gt; ALCL, enteropathy-associated T-cell lymphoma, primary cutaneous ALCL, and Sézary syndrome). Median age was 33 (range 10–68) for cHL and 31 (11–70) for MTCL. The median number of prior lines of therapy was 5 (2–18) in cHL and 4 (2–6) in MTCL. Bridging therapy (new therapy started between procurement and CAR-T infusion) was used in 15 cHL and 3 MTCL pts. In cHL pts, prior therapies—including bridging—included brentuximab vedotin (&lt;i&gt;n&lt;/i&gt; = 28), PD-1 inhibitor (PD-1i, &lt;i&gt;n&lt;/i&gt; = 23), bendamustine (&lt;i&gt;n&lt;/i&gt; = 18), autologous stem cell transplant (SCT, &lt;i&gt;n&lt;/i&gt; = 24), and alloSCT (&lt;i&gt;n&lt;/i&gt; = 10). At LD, 24 cHL and 4 MTCL pts had active disease (PR or worse) and were evaluable for response to CAR-T. 8 pts with cHL received benda LD; all others received flu/benda LD. Median vein-to-vein time (time from procurement to CAR-T infusion) was 84 days (40–337). 7 pts with cHL and 2 with MTCL were treated on DL1; all others on DL2.&lt;/p&gt;&lt;p&gt;In cHL pts, the CR rate with benda LD was 0/5; it was 15/19 with flu/benda LD. 2/4 pts with MTCL achieved CR.&lt;/p&gt;&lt;p&gt;Median follow-up was 6.6 years for cHL and 6.0 years for MTCL. For cHL, 6-year progression-free survival (PFS) was 19% (80% CI: 11–32), 6-year duration of response (DOR) was 25% (80% CI: 15–41), and 6-year overall survival (OS) was 84% (80% CI: 73–96) (Figure 1A–C). For MTCL, 6-year PFS was 50% (80% CI: 26–95), 6-year DOR was 67% (80% CI: 40–100), and 6-year OS was 67% (80% CI: 40–100) (Figure 1D–F). In pts with cHL, Flu/benda LD (HR: 0.47, 80% CI 0.26–0.85) and PD-1i ≤ 1 year before CAR-T (HR: 0.44, 80% CI: 0.25–0.79) were associated with superior PFS, whereas increasing lines of therapy and prior alloSCT were associated with inferior PFS (Figure 1G).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; CD30 CAR-T has encouraging activity and maintains durable re","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144291998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MULTI-TARGETED THERAPY WITH ViPOR IN MANTLE CELL LYMPHOMA (MCL); UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE (MRD)","authors":"C. Melani,&nbsp;R. Lakhotia,&nbsp;S. Pittaluga,&nbsp;J. D. Phelan,&nbsp;J. Muppidi,&nbsp;M. Gordon,&nbsp;Y. Yang,&nbsp;W. Xu,&nbsp;T. Davies-Hill,&nbsp;D. W. Huang,&nbsp;C. J. Thomas,&nbsp;M. Ceribelli,&nbsp;F. A. Tosto,&nbsp;A. M. Juanitez,&nbsp;A. Pradhan,&nbsp;C. Morrison,&nbsp;A. Tadese,&nbsp;C. A. Ramsower,&nbsp;L. M. Rimsza,&nbsp;A. Jacob,&nbsp;H. Simmons,&nbsp;E. S. Jaffe,&nbsp;M. Roschewski,&nbsp;L. M. Staudt,&nbsp;W. H. Wilson","doi":"10.1002/hon.70093_45","DOIUrl":"https://doi.org/10.1002/hon.70093_45","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Introduction:&lt;/b&gt; MCL is incurable with immunochemotherapy. Oral targeted agents are active but often do not induce durable remissions. We developed multi-agent targeted ViPOR and demonstrated safety and efficacy in MCL (Melani et al. &lt;i&gt;Blood&lt;/i&gt;. 2024). Here, we present new and updated efficacy and MRD data for the MCL cohort of our ongoing ViPOR study.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; Treatment-naïve (TN) and relapsed/refractory (R/R) MCL pts with adequate organ function were eligible. Venetoclax 400 mg was given PO D2-14 on C2-6 with an initial 12d ramp-up on C2 with fixed-dose ibrutinib 560 mg PO D1-14, prednisone 100 mg PO D1-7, obinutuzumab 1000 mg IV D1-2, and lenalidomide 15 mg PO D1-14 on C1-6 as previously described (Melani et al. &lt;i&gt;Blood.&lt;/i&gt; 2024). ViPOR q21d × 6C was given without maintenance. TLS ppx was given to all pts and G-CSF in R/R pts. Baseline CT, PET, BM, and tumor bx was performed with CT after C1, 2, 4, and 6 and PET after C6. CT was then performed q3m × 1y, q4m × 1y, q6m × 1y, and q12m × 2y. MRD was assessed in ctDNA from paired plasma and PBMC samples using clonoSEQ at baseline, during tx, and in f/u.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; 39 MCL pts (19 R/R &amp; 20 TN) enrolled. Median (range) age was 67y (41–82) with 69% male. Blastoid morphology, Ki-67 &gt; 30%, and TP53 aberration seen in 28%, 37%, and 33%, respectively. High-risk MIPI and MCL35 proliferation score seen in 31% and 20%, respectively. Median (range) prior tx in R/R was 3 (1–7) with prior BTKi in 42% and 63% refractory to last tx.&lt;/p&gt;&lt;p&gt;Heme AEs included G3-4 (% cycles) thrombocytopenia (15%), neutropenia (14%), and anemia (10%), with no febrile neutropenia across 212 cycles. The only non-heme G3 AE in &gt; 10% pts was hypokalemia (27%) and rash (14%). Non-heme AEs (% pts) included hypokalemia (92%), diarrhea (65%), and rash (59%). G3 A.fib occurred in 2 pts with 1 G3 VTE and no major bleeding. No TLS or tx-related mortality occurred. Dose reductions occurred in 27%, and 89% completed all 6C.&lt;/p&gt;&lt;p&gt;In 37 pts off-tx, ORR and CR rate were 100% (17/17) and 94% (16/17) in R/R and both 100% (20/20) in TN MCL. CRs occurred in all MIPI and MCL35 risk groups and high-risk subsets (Figure 1A). With a median f/u of 32 m, 81% of CRs are ongoing, with a 2y TTP, PFS, and OS of 93%, 66%, and 65%, respectively, in R/R, and 95%, 95%, and 100%, respectively, in TN MCL (Figure 1B). 2y TTP was 85% in MCL with elevated Ki-67, 80% in blastoid, and 100% in MCL with TP53 aberration.&lt;/p&gt;&lt;p&gt;In 36 MRD evaluable pts, 13%, 81%, and 97% were MRD undetectable after C1, C2, and at EOT. Median (range) duration of MRD negativity was 16 m (1–41). All 4 pts with relapse after CR experienced molecular relapse prior to imaging, with a median (range) lead-time of 2 m (0–6). MRD analysis using paired PMBCs will be presented at the meeting.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; Fixed-duration ViPOR × 6C induces a high rate of MRD undetectable CRs in MCL, including high-risk subsets. ViPOR with a 12d VEN ramp-up on C2 is s","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_45","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IDENTIFYING NURSING TRAINING NEEDS FOR THE MANAGEMENT OF BISPECIFIC DRUGS AND PATIENT FOLLOW-UP IN ONCO-HEMATOLOGY UNITS: A NON-INTERVENTIONAL, E-SURVEY BELL STUDY","authors":"M. Bou,&nbsp;P. Blázquez,&nbsp;J. Parra,&nbsp;M. T. San Miguel","doi":"10.1002/hon.70093_ON06","DOIUrl":"https://doi.org/10.1002/hon.70093_ON06","url":null,"abstract":"&lt;p&gt;M. Bou, P. Blázquez, J. Parra, and M. T. San Miguel equally contributing author.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Introduction:&lt;/b&gt; Advances in the treatment of oncohematological disorders such as non-Hodgkin lymphoma (NHL), driven by new cell therapies targeted with bispecific monoclonal antibodies (mAB), allow for a much more efficient, personalized and selective approach.&lt;/p&gt;&lt;p&gt;Its high response rate is indisputable, but potential adverse events (AEs) and associated toxicities require a precise monitoring as part of therapeutic management. In this monitoring, the role of the nursing professionals (NP) is fundamental. They actively participate in the management of symptoms, the interpretation of tests, and the advice to patients and families. In order for NPs to be able to effectively manage patients receiving bispecific mAB, it is essential to know what unmet needs are about this therapy in terms of learning, tools and training materials that, from their point of view, would contribute to improving quality and saitsfaction with their work.&lt;/p&gt;&lt;p&gt;The objective of this research is to identify specific training needs and potential knowledge gaps of NPs related with the management of LNH patients in treatment with bispecific mAb: mechanism of action, monitoring, identification and management of AEs, to establish an adequate care plan.&lt;/p&gt;&lt;p&gt;This study will provide valuable information on the training needs of oncohematological nursing, which will improve and facilitate the daily work of NPs.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; A cross-sectional observational study will be conducted with approximately 100 hospital NPs, invited to participate by Spanish nursing societies. Data will be collected using an electronic survey. In order to describe the profile of the study population, participants will be asked, about their time of experience as a nurse in oncohematology, as well as in the care of patients with NHL and in the management of bispecific drug therapy, among others.&lt;/p&gt;&lt;p&gt;To respond to the objective of the study, ad hoc questions have been designed to find out what knowledge/training resources NPs have or consider they would need regarding: (1) general information that allows them to better understand bispecific drug therapy and its mechanism of action; (2) administration and monitoring of bispecific drugs; (3) identification and management of the main AEs related to this therapy. Additionally, three hypothetical clinical cases will be presented to deepen their knowledge on the management of AEs.&lt;/p&gt;&lt;p&gt;This is a trial in progress. Data collection (fieldwork) is scheduled to take place between April and July 2025. Analysis of the results is expected to be available during the fourth quarter of 2025.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Research&lt;/b&gt; &lt;b&gt;funding declaration:&lt;/b&gt; This research is funded by Roche Farma S.A.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Keywords:&lt;/b&gt; Impact of New Therapies on Patient Care; Education and Training; Symptom Management and Supportive Care&lt;/p&gt;&lt;p&gt;&lt;b&gt;Potential sources of conflict of interest:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_ON06","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MULTI-OMIC PROFILING OF DARK ZONE LYMPHOMAS UNCOVERS DYSREGULATED GENE REGULATORY NETWORKS REFLECTING DZ-LZ B-CELL TRANSITION DYNAMICS","authors":"A. Fong,&nbsp;B. Collinge,&nbsp;L. K Hilton,&nbsp;S. Rai,&nbsp;C. Cassidy,&nbsp;S. Ben-Neriah,&nbsp;M. Boyle,&nbsp;A. Telenius,&nbsp;B. Meissner,&nbsp;P. Farinha,&nbsp;A. Lytle,&nbsp;G. Slack,&nbsp;L. Venturruti,&nbsp;A. Roth,&nbsp;C. Steidl,&nbsp;R. D Morin,&nbsp;D. W Scott","doi":"10.1002/hon.70093_19","DOIUrl":"https://doi.org/10.1002/hon.70093_19","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Introduction:&lt;/b&gt; Dark zone (DZ) lymphoma represents a subset of aggressive B-cell lymphomas characterized by a gene expression signature (DZsig) that resembles B cells from the DZ of the germinal center. This category includes Burkitt lymphoma (BL), most high-grade B-cell lymphomas with &lt;i&gt;MYC&lt;/i&gt; and &lt;i&gt;BCL2&lt;/i&gt; rearrangements (HGBCL-DH-&lt;i&gt;BCL2&lt;/i&gt;), and ∼15% of germinal center B-cell–like (GCB) cell-of-origin (COO) diffuse large B-cell lymphoma (DLBCL). DZsig+ GCB-DLBCL and HGBCL-DH-&lt;i&gt;BCL2&lt;/i&gt; are associated with poor outcomes, yet the biological mechanisms driving these outcomes are poorly understood. We hypothesize that their shared phenotype results from hijacking normal DZ B-cell programs. To investigate this hypothesis, we examined the biology of malignant B cells and the tumor microenvironment (TME) in DZsig+ lymphomas using disaggregated single nucleus (sn) multiome sequencing and CosMx spatial molecular imaging (SMI).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; DZsig and COO status was assigned by digital gene expression profiling. snMultiome sequencing was performed on 7 DZsig+ and 7 DZsig− biopsies. ArchR was used for transcription factor (TF) motif analysis, while SCENIC+ inferred enhancer-driven regulon (eRegulon) activities. Immunohistochemical (IHC) analysis of key TFs was used to validate findings in a cohort of 38 DZsig+ and 112 DZsig− biopsies of DLBCL morphology. To extend these findings, 749 biopsies were analyzed by CosMx SMI on tissue microarrays using a custom 6375-gene probe set. Whole-cell segmentation was performed using Mesmer. Community analysis was performed using spatial graphs constructed via Delaunay triangulation with edge-length thresholding.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; High FOXO1 and low B-cell receptor (BCR)/CD40-mediated eRegulon activities (NFκB1, REL, RELB, IRF4) emerged as defining features of DZsig+ lymphomas. These findings are supported by elevated FOXO1 motif accessibility and reduced NFκB1 and NFκB2 accessibility in DZsig+ lymphomas. Consistently, nuclear FOXO1 IHC positivity in our validation cohort was significantly higher in DZsig+ lymphomas and nuclear NFκB1 and NFκB2 IHC positivity was significantly lower in DZsig+ lymphomas compared to DZsig− GCB-DLBCL. SMI profiling revealed that DZsig+ lymphomas have an “immune cold” TME, contrasting with the “immune hot” TME of other GCB tumors. Community-level analysis further revealed a dichotomy, with DZsig+ lymphomas enriched in B-cell abundant clusters, while DZsig− GCB-DLBCL harbored diverse clusters composed of infiltrating T cell, macrophages, and stromal cells.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusion:&lt;/b&gt; These findings reveal divergent phenotypes mimicking different states within the GC DZ-light zone (LZ) continuum, where FOXO1 drives the DZ phenotype, and BCR/CD40-mediated signaling suppresses FOXO1 activity in the LZ. In DZsig+ lymphomas, this transition is skewed, with increased FOXO1 and decreased NFκB motif accessibility, sustaining a DZ-like state. An “immune cold” TME suggests the ","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_19","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SHORT-TERM DOSE-DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV- AND HIV+ PATIENTS WITH BURKITT LYMHOMA","authors":"P. Angelillo,&nbsp;F. Erbella,&nbsp;C. Pagani,&nbsp;E. Ravano,&nbsp;L. Verga,&nbsp;F. Cavallo,&nbsp;M. C. Quattrocchi,&nbsp;P. Fiore,&nbsp;C. Cattaneo,&nbsp;G. Rindone,&nbsp;E. Amaducci,&nbsp;F. Pagni,&nbsp;L. Bandiera,&nbsp;L. Pecciarini,&nbsp;A. Passi,&nbsp;S. Maifredi,&nbsp;L. Lorenzi,&nbsp;L. Bongiovanni,&nbsp;T. Calimeri,&nbsp;E. Flospergher,&nbsp;F. Marino,&nbsp;G. Cassanello,&nbsp;S. Marktel,&nbsp;S. Mastaglio,&nbsp;F. Palumbo,&nbsp;L. Saliani,&nbsp;M. Quattrone,&nbsp;A. Carmagnola,&nbsp;M. Ponzoni,&nbsp;M. Spina,&nbsp;A. Re,&nbsp;A. J. M. Ferreri","doi":"10.1002/hon.70094_287","DOIUrl":"https://doi.org/10.1002/hon.70094_287","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Introduction:&lt;/b&gt; Standard treatment for sporadic and immunodeficiency-associated Burkitt Lymphoma (BL) involves resource-heavy combinations, with long delivery times, and often dose-limiting toxicity, interruptions and increased treatment-related mortality (TRM), particularly in pts with large tumour burden or HIV infection. Over the last decade, BL pts have been treated with the dose-dense, short-term “CARMEN” therapy in Italian Centres. Positive safety and efficacy profiles in both HIV-negative and HIV/AIDS pts with BL have been reported [Ferreri et al. &lt;i&gt;Blood Adv&lt;/i&gt;. 2022]. In a situation where comparative prospective trials are impractical, we analysed the feasibility, toxicity and efficacy of CARMEN and 4 other intensified regimens in BL pts treated at the 6 Italian centres where the CARMEN program was developed.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; Pts ≤ 70 yo with BL treated with curative intent between 03/2009 and 10/2024 were included. CARMEN regimen details were previously reported (Ferreri et al. &lt;i&gt;Blood Adv&lt;/i&gt;. 2022). Pts treated with other anthracycline-containing intensified regimens served as controls. Toxic deaths, interruptions/dose reductions, G ≥ 3 non-hematological toxicity, and G ≥ 3 infections were used to define feasibility and tolerability (Table).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; The study population included 153 consecutive BL pts treated with curative intent (median 48 ys, range 19–69; 116 males): 57 received CARMEN and 96 received other regimens: 73 GMALL, 13 R-HyperCVAD, 5 R-daEPOCH, 5 CODOXM-IVAC). Fifty-seven pts had HIV. There were no differences between CARMEN and controls in age (median: 43 vs. 49 yo), PS 2–4 (41% vs. 45%), advanced stage (86% vs. 78%), extranodal disease (86% vs. 77%), CNS involvement (14% vs. 11%), high LDH serum level (74% vs. 79%), and bulky disease (44% vs. 32%). CARMEN showed better feasibility, with only 11% requiring dose reduction or interruption, compared to 36% in other regimens (Table). It was also better tolerated, with significantly lower rates of G ≥ 3 infections and non-hematological toxicities, both in HIV+ pts and the entire series, along with lower opportunistic infections in HIV+ pts.&lt;/p&gt;&lt;p&gt;At a median follow-up of 84 (10–189) months, 39 CARMEN pts and 63 controls were relapse-free, with 5-yr PFS of 68% (95% CI: 66–70) and 66% (95% CI: 64–68), respectively. Of 109 pts alive: 42 were after CARMEN and 67 after other treatments, with 5-yr OS of 74% (95% CI: 73–75) and 69% (95% CI: 68–70), respectively (Figure A). HIV+ pts showed a trend to worse survival, but CARMEN was not inferior to the other combinations in this high-risk population (Figure B).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; With the limitations of a retrospective cohort, this study shows that CARMEN achieves comparable outcomes to other standard intensified regimens, with significantly better tolerability in both HIV-negative and HIV+ BL pts. In addition to its short duration and good tolerability, CARMEN may reduce the risk of chronic toxicit","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70094_287","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}